Skyline Dx to Spend $7.2M in New Funds on Clinical Trials for Array-Based AML Test, Operations

The molecular diagnostics company, based in Rotterdam, the Netherlands, will use the proceeds to fund additional validation studies of its Affymetrix-manufactured test for acute myeloid leukemia, as well as to flesh out its business-development team as it ramps up for an eventual US launch.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.